An intronic G run within HI1V-1 intron 2 is critical for splicing regulation of vif mRNA

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2707-2720

  Widera, Marek ^a   Erkelenz, Steffen ^a   Hillebrand, Frank ^a   Krikoni, Aikaterini ^a   Widera, Darius ^b   Kaisers, Wolfgang ^a   Deenen, René ^a   Gombert, Michael ^a   Dellen, Rafael ^a   Pfeiffer, Tanya ^c   Kaltschmidt, Barbara ^b   Münk, Carsten ^a   Bosch, Valerie ^c   Köhrer, Karl ^a   Schaal, Heiner ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GLYCOPROTEIN GP 41; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H; LUCIFERASE; MESSENGER RNA; REV PROTEIN; REV4B PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN;

5' SPLICE SITE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRON; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA DEEP SEQUENCING; RNA PROCESSING; RNA SEQUENCE; RNA SPLICING; T LYMPHOCYTE; UPREGULATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; CELL LINE; CYTIDINE DEAMINASE; HEK293 CELLS; HELA CELLS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; INTRONS; JURKAT CELLS; MOLECULAR SEQUENCE DATA; MUTATION; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA SPLICE SITES; RNA SPLICING; RNA, MESSENGER; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; T-LYMPHOCYTES; UP-REGULATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84874694554     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02755-12     Document Type: Article

References (81)

1. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, Konig R, Flory E. 2011. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7:e1002425.
2. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480:379 -382.
3. Kirchhoff F. 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8:55- 67.
4. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657.
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
6. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22:367-377.
7. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.
8. Münk C, Willemsen A, Bravo IG. 2012. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol. 12:71.
9. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci. 32:118-128.
10. Wissing S, Galloway NL, Greene WC. 2010. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol. Aspects Med. 31:383-397.
11. Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K. 2004. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J. Biol. Chem. 279:12355-12362.
12. JÄger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481:365-370.
13. Clerc I, Laverdure S, Torresilla C, Landry S, Borel S, Vargas A, Arpin- Andre C, Gay B, Briant L, Gross A, Barbeau B, Mesnard JM. 2011. Polarized expression of the membrane ASP protein derived from HIV-1 antisense transcription in T cells. Retrovirology 8:74.
14. Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamic RNP machine. Cell 136:701-718.
15. Michaud S, Reed R. 1991. An ATP-independent complex commits premRNA to the mammalian spliceosome assembly pathway. Genes Dev. 5:2534-2546.
16. Hoffman BE, Grabowski PJ. 1992. U1 snRNP targets an essential splicingfactor, U2AF65, to the 3= splice site by a network of interactions spanning the exon. Genes Dev. 6:2554-2568.
17. Robberson BL, Cote GJ, Berget SM. 1990. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol. Cell. Biol. 10:84-94.
18. Kammler S, Otte M, Hauber I, Kjems J, Hauber J, Schaal H. 2006. The strength of the HIV-1 3= splice sites affects Rev function. Retrovirology 3:89.
19. Cullen BR. 2003. Nuclear mRNA export: insights from virology. Trends Biochem Sci. 28:419-424.
20. Hoffmann D, Schwarck D, Banning C, Brenner M, Mariyanna L, Krepstakies M, Schindler M, Millar DP, Hauber J. 2012. Formation of trans-activation competent HIV-1 Rev:RRE complexes requires the recruitment of multiple protein activation domains. PLoS One 7:e38305.
21. Pollard VW, Malim MH. 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52:491-532.
22. Exline CM, Feng Z, Stoltzfus CM. 2008. Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression. J. Virol. 82:3921-3931.
23. Mandal D, Exline CM, Feng Z, Stoltzfus CM. 2009. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5= splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G. J. Virol. 83:6067- 6078.
24. Asang C, Hauber I, Schaal H. 2008. Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer. Nucleic Acids Res. 36:1450- 1463.
25. Domsic JK, Wang Y, Mayeda A, Krainer AR, Stoltzfus CM. 2003. Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. Mol. Cell. Biol. 23:8762- 8772.
26. Motta-Mena LB, Smith SA, Mallory MJ, Jackson J, Wang J, Lynch KW. 2011. A disease-associated polymorphism alters splicing of the human CD45phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). J. Biol. Chem. 286:20043- 20053.
27. Sharma S, Kohlstaedt LA, Damianov A, Rio DC, Black DL. 2008. Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome. Nat. Struct. Mol. Biol. 15: 183-191.
28. Sharma S, Maris C, Allain FH, Black DL. 2011. U1 snRNA directly interacts with polypyrimidine tract-binding protein during splicing repression. Mol. Cell 41:579-588.
29. Purcell DF, Martin MA. 1993. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67:6365- 6378.
30. Schaub MC, Lopez SR, Caputi M. 2007. Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes. J. Biol. Chem. 282:13617-13626.
31. Caputi M, Zahler AM. 2001. Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H'/F/ 2H9 family. J. Biol. Chem. 276:43850-43859.
32. Carlo T, Sterner DA, Berget SM. 1996. An intron splicing enhancer containing a G-rich repeat facilitates inclusion of a vertebrate micro-exon. RNA 2:342-353.
33. Chen CD, Kobayashi R, Helfman DM. 1999. Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene. Genes Dev. 13:593- 606.
34. Del Gatto F, Breathnach R. 1995. Exon and intron sequences, respectively, repress and activate splicing of a fibroblast growth factor receptor 2 alternative exon. Mol. Cell. Biol. 15:4825- 4834.
35. Marcucci R, Baralle FE, Romano M. 2007. Complex splicing control of the human thrombopoietin gene by intronic G runs. Nucleic Acids Res. 35:132-142.
36. McCarthy EM, Phillips JA, III. 1998. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum. Mol. Genet. 7:1491-1496.
37. McCullough AJ, Berget SM. 1997. G triplets located throughout a class of small vertebrate introns enforce intron borders and regulate splice site selection. Mol. Cell. Biol. 17:4562- 4571.
38. McCullough AJ, Berget SM. 2000. An intronic splicing enhancer binds U1 snRNPs to enhance splicing and select 5= splice sites. Mol. Cell. Biol. 20:9225-9235.
39. Chou MY, Rooke N, Turck CW, Black DL. 1999. hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells. Mol. Cell. Biol. 19:69-77.
40. Garneau D, Revil T, Fisette JF, Chabot B. 2005. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 280:22641-22650.
41. Han K, Yeo G, An P, Burge CB, Grabowski PJ. 2005. A combinatorial code for splicing silencing: UAGG and GGGG motifs. PLoS Biol. 3:e158.
42. Hastings ML, Wilson CM, Munroe SH. 2001. A purine-rich intronic element enhances alternative splicing of thyroid hormone receptor mRNA. RNA 7:859-874.
43. Min H, Chan RC, Black DL. 1995. The generally expressed hnRNP F is involved in a neural-specific pre-mRNA splicing event. Genes Dev. 9:2659-2671.
44. Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. 2009. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat. Struct. Mol. Biol. 16:1094-1100.
45. Yeo G, Burge CB. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11:377- 394.
46. Zhang XH, Leslie CS, Chasin LA. 2005. Computational searches for splicing signals. Methods 37:292-305.
47. Jablonski JA, Caputi M. 2009. Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. J. Virol. 83:981-992.
48. Lund N, Milev MP, Wong R, Sanmuganantham T, Woolaway K, Chabot B, Abou Elela S, Mouland AJ, Cochrane A. 2012. Differential effects of hnRNP D/AUF1 isoforms on HIV-1 gene expression. Nucleic Acids Res. 40:3663-3675.
49. Jacquenet S, Mereau A, Bilodeau PS, Damier L, Stoltzfus CM, Branlant C. 2001. A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. J. Biol. Chem. 276:40464-40475.
50. Caputi M, Zahler AM. 2002. SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. EMBO J. 21:845- 855.
51. Asang C, Erkelenz S, Schaal H. 2012. The HIV-1 major splice donor D1 is activated by splicing enhancer elements within the leader region and the p17-inhibitory sequence. Virology 432:133-145.
52. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
53. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze- Osthoff K, Schaal H, Schwerk C. 2010. Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. RNA 16:2442-2454.
54. Krummheuer J, Lenz C, Kammler S, Scheid A, Schaal H. 2001. Influence of the small leader exons 2 and 3 on human immunodeficiency virus type 1 gene expression. Virology 286:276-289.
55. Selden RF, Howie KB, Rowe ME, Goodman HM, Moore DD. 1986. Human growth hormone as a reporter gene in regulation studies employing transient gene expression. Mol. Cell. Biol. 6:3173-3179.
56. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
57. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
58. Goncalves J, Jallepalli P, Gabuzda DH. 1994. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68:704- 712.
59. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27.
60. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870-5874.
61. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, Lewis GK. 1994. Epitope mapping and topol-ogy of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res. Hum. Retrovir. 10:371-381.
62. Holtkotte D, Pfeiffer T, Bosch V. 2007. Cell-free infectivity of HIV type 1 produced in nonpermissive cells is only moderately impacted by C-terminal Env truncation despite abrogation of viral spread. AIDS Res. Hum. Retrovir. 23:729-740.
63. Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp M, Meyer I, Gierling W, Theiss S, Preuss T, Schindler D, Kjems J, Schaal H. 2003. A novel approach to describe a U1 snRNA binding site. Nucleic Acids Res. 31:6963- 6975.
64. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
65. Tremblay M, Sullivan AK, Rooke R, Geleziunas R, Tsoukas C, Shematek G, Gilmore N, Wainberg MA. 1989. New CD4(+) cell line susceptible to infection by HIV-1. J. Med. Virol. 28:243-249.
66. Haché G, Harris RS. 2009. CEM-T4 cells do not lack an APOBEC3G cofactor. PLoS Pathog. 5:e1000528.
67. Benko DM, Schwartz S, Pavlakis GN, Felber BK. 1990. A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J. Virol. 64:2505-2518.
68. Lützelberger M, Reinert LS, Das AT, Berkhout B, Kjems J. 2006. A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability. J. Biol. Chem. 281:18644-18651.
69. Wilk T, Pfeiffer T, Bosch V. 1992. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 189:167-177.
70. Madsen JM, Stoltzfus CM. 2006. A suboptimal 5= splice site downstream of HIV-1 splice site A1 is required for unspliced viralmRNAaccumulation and efficient virus replication. Retrovirology 3:10.
71. Mandal D, Feng Z, Stoltzfus CM. 2010. Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs. J. Virol. 84:12790-12800.
72. Voelker RB, Erkelenz S, Reynoso V, Schaal H, Berglund JA. 2012. Frequent gain and loss of intronic splicing regulatory elements during the evolution of vertebrates. Genome Biol Evol. 4:659-674.
73. Wang E, Mueller WF, Hertel KJ, Cambi F. 2011. G run-mediated recognition of proteolipid protein and DM20 5= splice sites by U1 small nuclear RNA is regulated by context and proximity to the splice site. J. Biol. Chem. 286:4059-4071.
74. Chang ST, Sova P, Peng X, Weiss J, Law GL, Palermo RE, Katze MG. 2011. Next-generation sequencing reveals HIV-1-mediated suppression of T cell activation andRNAprocessing and regulation of noncodingRNA expression in a CD4+ T cell line. mBio 2(5):e00134-11. doi:10.1128/mBio .00134-11.
75. Kammler S, Leurs C, Freund M, Krummheuer J, Seidel K, Tange TO, Lund MK, Kjems J, Scheid A, Schaal H. 2001. The sequence complementarity between HIV-1 5= splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA 7:421- 434.
76. Buratti E, Baralle M, De Conti L, Baralle D, Romano M, Ayala YM, Baralle FE. 2004. hnRNP H binding at the 5= splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes. Nucleic Acids Res. 32:4224-4236.
77. Dowling D, Nasr-Esfahani S, Tan CH, O'Brien K, Howard JL, Jans DA, Purcell DF, Stoltzfus CM, Sonza S. 2008. HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. Retrovirology 5:18.
78. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE. 1965. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529.
79. Nara PL, Hatch WC, Dunlop NM, Robey WG, Fischinger PJ. 1987. Simple, rapid quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retroviruses 3:283-302.
80. Nara PL, Fischinger PJ. 1988. Quantitative infectivity assay for HIV-1 and -2. Nature 332:469-470.
81. Erkelenz S, Poschmann G, Theiss S, Stefanski A, Hillebrand F, Otte M, Stühler K, Schaal H. 2013. Tra2-mediated recognition of HIV-1 5= splice site D3 as a key factor in the processing of vpr mRNA. J. Virol. 87:2721- 2734.